|
DE19531277A1
(de)
|
1995-08-25 |
1997-02-27 |
Basf Ag |
Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
|
|
DE19536387A1
(de)
*
|
1995-09-29 |
1997-04-03 |
Basf Ag |
Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
|
|
CA2214895C
(en)
*
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
|
TW568788B
(en)
*
|
1998-10-12 |
2004-01-01 |
Chugai Pharmaceutical Co Ltd |
Polymer combining with phosphoric acid and preparation containing the same
|
|
JP3572213B2
(ja)
*
|
1999-01-18 |
2004-09-29 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロース
|
|
US6733789B1
(en)
|
1999-01-21 |
2004-05-11 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
DE19916383A1
(de)
*
|
1999-03-31 |
2000-10-05 |
Schering Ag |
Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
|
|
JP2000327701A
(ja)
*
|
1999-05-18 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
低置換度ヒドロキシプロピルセルロース及び固形製剤
|
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
|
DE19934610A1
(de)
*
|
1999-07-23 |
2001-01-25 |
Bayer Ag |
Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
|
|
BR0013488A
(pt)
|
1999-08-24 |
2002-05-07 |
Siemens Ag |
Equipamento de aspiração para um motor de combustão interna
|
|
TR200200763T2
(tr)
*
|
1999-09-24 |
2003-09-22 |
Janssen Pharmaceutica N.V. |
Antiviral bileşimler
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
EP1175205B1
(en)
*
|
1999-11-12 |
2006-06-14 |
Abbott Laboratories |
Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
|
|
US20040185099A1
(en)
*
|
2000-01-20 |
2004-09-23 |
Biovail Laboratories, Inc. |
Multiparticulate bisoprolol formulation
|
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
US7842308B2
(en)
*
|
2001-01-30 |
2010-11-30 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
US7883721B2
(en)
|
2001-01-30 |
2011-02-08 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
US20050175687A1
(en)
*
|
2001-01-30 |
2005-08-11 |
Mcallister Stephen M. |
Pharmaceutical formulations
|
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
|
US7067148B2
(en)
*
|
2001-02-15 |
2006-06-27 |
King Pharmaceutical Research & Development, Inc. |
Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
|
|
JP2004534812A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
薬物および中性ポリマーの分散物の医薬組成物
|
|
CA2450748A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions containing polymer and drug assemblies
|
|
US20030198671A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique plasma AUC properties
|
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
|
US7101569B2
(en)
|
2001-08-14 |
2006-09-05 |
Franz G Andrew |
Methods of administering levothyroxine pharmaceutical compositions
|
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
|
US20030180356A1
(en)
*
|
2001-10-29 |
2003-09-25 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
|
US20030091633A1
(en)
*
|
2001-11-15 |
2003-05-15 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
|
US20030118652A1
(en)
*
|
2001-11-15 |
2003-06-26 |
John Kelly |
Methods and compositions for use of (S)-bisoprolol
|
|
CN1625397A
(zh)
|
2002-02-01 |
2005-06-08 |
辉瑞产品公司 |
胆固醇酯转移蛋白抑制剂的控制释放药物剂型
|
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
KR20040011248A
(ko)
*
|
2002-07-30 |
2004-02-05 |
환인제약 주식회사 |
암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
|
|
EP1530457B1
(en)
|
2002-08-12 |
2009-09-09 |
Bend Research, Inc. |
Pharmaceutical compositions of drugs in semi-ordered form and polymers
|
|
AU2003263162B2
(en)
|
2002-10-24 |
2009-05-07 |
Immupharm A/S |
Pharmaceutical compositions comprising flavonoids and menthol
|
|
JP2006513186A
(ja)
|
2002-12-20 |
2006-04-20 |
ファイザー・プロダクツ・インク |
Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形
|
|
US7423004B2
(en)
*
|
2003-01-31 |
2008-09-09 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
|
TW200526274A
(en)
|
2003-07-21 |
2005-08-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
NZ546677A
(en)
*
|
2003-11-14 |
2008-11-28 |
Pfizer Prod Inc |
Solid amorphous dispersions of an MTP inhibitor for treatment of obesity
|
|
BRPI0417492A
(pt)
*
|
2003-12-09 |
2007-05-29 |
Pfizer |
composições compreendendo um inibidor de protease de hiv
|
|
AP2006003685A0
(en)
|
2004-02-04 |
2006-08-31 |
Pfizer Prod Inc |
Substituted quinoline compounds
|
|
PE20060003A1
(es)
|
2004-03-12 |
2006-03-01 |
Smithkline Beecham Plc |
Formulacion farmaceutica polimerica para moldear por inyeccion
|
|
AP2006003768A0
(en)
|
2004-05-25 |
2006-10-31 |
Pfizer Prod Inc |
TetraazabenzoÄeÜazulene derivatives and analogs tehereof
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
JP2008509207A
(ja)
*
|
2004-08-12 |
2008-03-27 |
レキット ベンキーザー ヘルスケア (ユーケイ) リミテッド |
溶融押出しにより作製するパラセタモール、nsaid及び糖アルコールを含む顆粒
|
|
PT1941798E
(pt)
|
2004-12-17 |
2012-08-22 |
Devgen Nv |
Composições nematodicidas
|
|
WO2006082518A1
(en)
|
2005-02-03 |
2006-08-10 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
NZ562304A
(en)
*
|
2005-05-10 |
2010-06-25 |
Novartis Ag |
Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
|
|
CN101484142B
(zh)
|
2006-03-24 |
2013-06-05 |
奥克思利尤姆国际控股公司 |
包含对碱性不稳定的药物的稳定组合物
|
|
US8465759B2
(en)
*
|
2006-03-24 |
2013-06-18 |
Auxilium Us Holdings, Llc |
Process for the preparation of a hot-melt extruded laminate
|
|
CN101460149A
(zh)
*
|
2006-06-07 |
2009-06-17 |
巴斯夫欧洲公司 |
醋酸乙烯酯-磺酸盐共聚物作为微水溶性化合物的加溶剂的用途
|
|
US8343547B2
(en)
*
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
|
US7638541B2
(en)
*
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
WO2009007328A2
(de)
*
|
2007-07-06 |
2009-01-15 |
Basf Se |
Verwendung von homo- und copolymeren zur stabilisierung von wirkstoffformulierungen
|
|
AU2008279447A1
(en)
*
|
2007-07-19 |
2009-01-29 |
Metabolex, Inc. |
N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
|
|
EP2219624A2
(en)
|
2007-11-08 |
2010-08-25 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
|
CA2713128C
(en)
|
2008-01-25 |
2016-04-05 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
|
AU2009231906A1
(en)
*
|
2008-03-31 |
2009-10-08 |
Metabolex, Inc. |
Oxymethylene aryl compounds and uses thereof
|
|
AU2009243681B2
(en)
|
2008-05-09 |
2013-12-19 |
Grunenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
|
AU2009256572A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Capsugel Belgium Nv |
Hydroxypropyl cellulose capsule shell
|
|
RU2491918C2
(ru)
*
|
2008-07-03 |
2013-09-10 |
Новартис Аг |
Способ грануляции из расплава
|
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
KR101738369B1
(ko)
|
2009-07-22 |
2017-05-22 |
그뤼넨탈 게엠베하 |
핫 멜트 압출된 제어 방출 투여형
|
|
CN102639118B
(zh)
|
2009-07-22 |
2015-07-29 |
格吕伦塔尔有限公司 |
氧化稳定的抗干扰剂型
|
|
JP5909185B2
(ja)
|
2009-10-01 |
2016-04-26 |
シマベイ セラピューティクス, インコーポレーテッド |
置換テトラゾール−1−イルフェノキシメチルチアゾール−2−イルピペリジニルピリミジン塩
|
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
|
JP5847813B2
(ja)
|
2010-06-23 |
2016-01-27 |
シマベイ セラピューティクス, インコーポレーテッド |
5−エチル−2−{4−[4−(4−テトラゾル−1−イル−フェノキシメチル)−チアゾール−2−イル]−ピペリジン−1−イル}−ピリミジンの組成物
|
|
BR112013005194A2
(pt)
|
2010-09-02 |
2016-05-03 |
Gruenenthal Gmbh |
forma de dosagem resistente à violação compreendendo sal inorgânico
|
|
TWI516286B
(zh)
|
2010-09-02 |
2016-01-11 |
歌林達股份有限公司 |
含陰離子聚合物之抗破碎劑型
|
|
US10463739B2
(en)
|
2010-12-23 |
2019-11-05 |
AbbVie Deutschland GmbH & Co. KG |
Solid retard formulations based on solid dispersions
|
|
CA2824639A1
(en)
|
2011-02-17 |
2012-08-23 |
Ashish Chatterji |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
|
BR112013023879B1
(pt)
*
|
2011-03-21 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
Preparações sólidas que contém ambroxol, seu método de preparação, forma de dosagem farmacêutica e seus usos
|
|
BR112014001091A2
(pt)
|
2011-07-29 |
2017-02-14 |
Gruenenthal Gmbh |
comprimido resistente à adulteração que fornece liberação imediata do fármaco
|
|
EA201400172A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
|
EA201400990A1
(ru)
|
2012-04-06 |
2015-01-30 |
Пфайзер Инк. |
Ингибиторы диацилглицеринацилтрансферазы 2
|
|
EP2838512B1
(en)
|
2012-04-18 |
2018-08-22 |
Grünenthal GmbH |
Tamper resistant and dose-dumping resistant pharmaceutical dosage form
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
CN104812909A
(zh)
*
|
2012-11-27 |
2015-07-29 |
帝斯曼知识产权资产管理有限公司 |
用于生产离散固体挤出颗粒的方法
|
|
EP3003279A1
(en)
|
2013-05-29 |
2016-04-13 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
|
US9737490B2
(en)
|
2013-05-29 |
2017-08-22 |
Grünenthal GmbH |
Tamper resistant dosage form with bimodal release profile
|
|
PT3006049T
(pt)
*
|
2013-06-03 |
2018-03-20 |
Shinetsu Chemical Co |
Composição para extrusão por fusão a quente e método para produzir um produto extrudido por fusão a quente
|
|
BR112016000194A8
(pt)
|
2013-07-12 |
2019-12-31 |
Gruenenthal Gmbh |
forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
|
|
CN105744847A
(zh)
*
|
2013-11-15 |
2016-07-06 |
帝斯曼知识产权资产管理有限公司 |
通过热熔挤出获得的略溶化合物的制剂
|
|
EP3073994A1
(en)
|
2013-11-26 |
2016-10-05 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
|
LT3119757T
(lt)
|
2014-03-17 |
2018-07-10 |
Pfizer Inc. |
Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
|
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
|
EA201692388A1
(ru)
|
2014-05-26 |
2017-05-31 |
Грюненталь Гмбх |
Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
|
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
|
BR112018006720B1
(pt)
*
|
2015-10-07 |
2023-05-02 |
Dsm Ip Assets B.V |
Extrusados multivitamínicos, alimento, ração, formulações para cuidado pessoal e/ou farmacológicas ou pré-misturas dos mesmos
|
|
AU2017305392A1
(en)
|
2016-08-03 |
2019-02-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
WO2018115130A1
(en)
|
2016-12-23 |
2018-06-28 |
Hermes Arzneimittel Gmbh |
Oral pharmaceutical composition with improved taste-masking properties
|
|
AU2018230236B2
(en)
|
2017-03-10 |
2022-05-19 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as LRRK2 inhibitors
|
|
US11254660B2
(en)
|
2018-08-31 |
2022-02-22 |
Pfizer Inc. |
Combinations for treatment of NASH/NAFLD and related diseases
|
|
JP2022529930A
(ja)
|
2019-04-19 |
2022-06-27 |
ファイザー・インク |
Pahを処置するための抗増殖薬
|
|
WO2020234726A1
(en)
|
2019-05-20 |
2020-11-26 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
|
WO2020261144A1
(en)
|
2019-06-28 |
2020-12-30 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
|
JP7288554B1
(ja)
|
2020-06-09 |
2023-06-07 |
ファイザー・インク |
メラノコルチン4受容体アンタゴニストとしてのスピロ化合物およびそれらの使用
|
|
CA3240990A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
|
JP2024544021A
(ja)
|
2021-12-06 |
2024-11-26 |
ファイザー・インク |
メラノコルチン4受容体アンタゴニストおよびそれらの使用
|
|
KR20250075705A
(ko)
|
2022-10-07 |
2025-05-28 |
화이자 인코포레이티드 |
Hsd17b13 억제제 및/또는 분해제
|
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
|
AU2023364628A1
(en)
|
2022-10-18 |
2025-04-03 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
|
EP4634169A1
(en)
|
2022-12-16 |
2025-10-22 |
Pfizer Inc. |
3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
|